CENTOGENE is one of the largest genetic biotech companies worldwide, the European market leader, and one of the global leaders in genetic diagnostic analyses of rare inherited diseases. Transforming global genetic data into medical decisions, that are focused on creating broader awareness for patients of all ethnicities around the world.
CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical, genetic, and multiomics data to diagnose, understand, and treat rare diseases. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge and data. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with over 3.9 billion weighted data points from approximately 600,000 patients representing over 120 different countries
The Company´s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, as well as a biobank of patients´ blood samples and cell cultures. CENTOGENE believes this represents the only platform focused on the comprehensive analysis of multi-level data to improve the understanding of rare hereditary diseases. It allows for better identification and stratification of patients and their underlying diseases to enable and accelerate discovery, development, and access to orphan drugs.
CENTOGENE was founded in 2006 and through an IPO in 2019 listed as a public company at NASDAQ (CNTG).